NK-92

NK-92 is a proprietary, permanent, interleukin-2 (IL-2)-dependent human natural killer (NK) cell line derived in 1992 from the peripheral blood of a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma. It is characterized by its cytotoxic activity against a broad spectrum of tumor targets and is used as an "off-the-shelf" adoptive cell therapy for cancer. The cells are activated, allogeneic, and require IL-2 for survival and proliferation. Mechanistically, NK-92 cells kill target cells by secreting perforin and granzymes to induce apoptosis in cancerous or infected cells; they also produce cytokines such as TNF-alpha and interferon-gamma to stimulate other immune responses. Unlike primary NK cells, NK-92 lacks most inhibitory receptors (KIR-negative), contributing to their potent cytotoxicity against leukemia, lymphoma, myeloma cell lines, and primary leukemic blasts. Clinical trials have demonstrated safety and some efficacy in refractory hematological malignancies[1][3][5][6]. Developed by Hans Klingemann/British Columbia Cancer Agency. Manufactured by ATCC.

Brand names

NK-92NK92NK 92NK-92®

Other names

allogeneic natural killer cell line NK-92